John Gilmore Premium NEW YORK – Following the completion of a $16 million Series A financing round earlier this week, startup NephroSant now expects to launch its Qsant kidney transplant rejection prediction assay as a laboratory-developed…
NEW YORK – Nephrosant said on Tuesday that it has closed an oversubscribed $16 million Series A funding round. The financing round was led by DaVita, with participation from DigitalDx Ventures and other previous investors. The…
SAN FRANCISCO – Bay Area startup Nephrosant, a University of California, San Francisco spinout, aims to launch its first noninvasive test for detecting kidney injury by early next year. Nephrosant, formerly known as KIT Bio, has…
